PulmoCADx, Inc.

PulmoCADx develops software tools for early non-invasive diagnosis of lung cancer. PulmoCADx Computer-Assisted Diagnosis (CAD) system analyzes thoracic CT scans and assists radiologists in detection and diagnosis of malignant lung nodules. Our software solution helps to make better diagnostic decision in order to initiate treatment earlier, and thus to improve treatment outcomes, as well as significantly reduce the number of follow-up CT scans and unnecessary needle biopsies. PulmoCADx competitive advantages: • Automatic detection of lung nodules in 3D • Registration of images with the compensation for lung expansion/contraction and patient movement, which results in accurate tracking of individual nodules • Measuring and taking into account multiple physiological and morphological parameters in addition to nodule growth measurements in order to determine whether a nodule is benign or malignant • Non-bias quantitative analysis of the data PulmoCADx value proposition: • Inexpensive solution to a common and costly medical problem • Allows to diagnose lung cancer and start treatment earlier, thus saving lives • Reduces false-positives and thus unnecessary and dangerous invasive diagnostic procedures • Reduces medical errors • Saves time for both patients and physicians • Minimizes overall healthcare expenses

• Employees 0
• Founded 2010
• Annual Revenue $10000000